NSABP FB-14
NSABP FB-14
A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer
Protocol Chair: Leisha A. Evans, MD, PhD
Protocol Officer: Samuel Jacobs, MD
Patient Population:
Patients with advanced triple-negative breast cancer
Target Accrual: 29 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT04024800
A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer
Protocol Chair: Leisha A. Evans, MD, PhD
Protocol Officer: Samuel Jacobs, MD
Patient Population:
Patients with advanced triple-negative breast cancer
Target Accrual: 29 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT04024800